Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
SurvivorNet on MSN6mon
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali17, 2025, explaining how the new drug combo has been approved for “hormone receptor-positive/human epidermal growth factor ...
Greenwich LifeSciences (GLSI) announced the following update on FLAMINGO-01 open label safety data. The FLAMINGO-01 DSMB met twice in 2024, ...
The universal cell-cycle inhibitor p21 Cip1/WAF1 is phosphorylated and localized in the cytoplasm in Her2/neu-overexpressing breast cancers as a result of its physical association with the ...
In close collaboration with the lab of Nai-Kong Cheung at MSK and Dane Wittrup at MIT, we have successfully applied this platform in three preclinical tumor models: GPA33 antigen (colorectal cancer); ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback